GSA Capital Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$588K	Buy	101,438 +66,773	+193%	+$443K	0.04%	812
2025 Q4	$272K	Sell	34,665 -34,051	-50%	-$268K	0.02%	1225
2025 Q3	$559K	Buy	68,716 +6,394	+10%	+$42.5K	0.05%	771
2025 Q2	$291K	Sell	62,322 -76,413	-55%	-$350K	0.02%	1271
2025 Q1	$762K	Buy	138,735 +88,892	+178%	+$359K	0.07%	516
2024 Q4	$169K	Buy	49,843 +22,493	+82%	+$72.4K	0.01%	1453
2024 Q3	$78K	Sell	27,350 -578,313	-95%	-$1.49M	0.01%	1506
2024 Q2	$1.36M	Buy	605,663 +593,952	+5,072%	+$1.2M	0.1%	314
2024 Q1	$26K	Sell	11,711 -404,556	-97%	-$1.05M	﹤0.01%	1550
2023 Q4	$978K	Buy	416,267 +35,036	+9%	+$64.7K	0.08%	409
2023 Q3	$709K	Buy	381,231 +348,016	+1,048%	+$797K	0.06%	585
2023 Q2	$87K	Sell	33,215 -282,810	-89%	-$720K	0.01%	1385
2023 Q1	$515K	Buy	+316,025	New	+$396K	0.05%	694
2022 Q4	–	Sell	-50,094	Closed	-$78K	–	1946
2022 Q3	$78K	Buy	50,094 +5,458	+12%	+$9.03K	0.01%	1389
2022 Q2	$69K	Sell	44,636 -72,671	-62%	-$153K	0.01%	1262
2022 Q1	$300K	Buy	117,307 +6,035	+5%	+$14.7K	0.04%	893
2021 Q4	$326K	Buy	+111,272	New	+$240K	0.04%	876
2021 Q3	–	Sell	-173,318	Closed	-$705K	–	1821
2021 Q2	$705K	Buy	173,318 +85,121	+97%	+$325K	0.08%	416
2021 Q1	$398K	Buy	+88,197	New	+$476K	0.07%	475
2020 Q2	–	Sell	-69,800	Closed	-$136K	–	1169
2020 Q1	$136K	Buy	69,800 +22,222	+47%	+$95.6K	0.03%	844
2019 Q4	$335K	Buy	+47,578	New	+$393K	0.04%	940